De­lay brings suc­cess for Roche as it fi­nal­ly wins FDA nod for Tecen­triq reg­i­men in front­line lung can­cer

Roche’s ea­ger­ly-an­tic­i­pat­ed ap­proval for a com­bi­na­tion of its im­munother­a­py Tecen­triq and an­ti-VEGF Avastin in ad­di­tion to chemother­a­py in front­line lung can­cer is fi­nal­ly here …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER